Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Kuwait to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for bronchodilator drugs in Kuwait has been growing steadily in recent years due to various factors.
Customer preferences: Patients in Kuwait prefer bronchodilator drugs that are easy to use and provide quick relief from respiratory symptoms. They also prefer drugs that have fewer side effects and are affordable.
Trends in the market: The bronchodilator drugs market in Kuwait is witnessing a shift towards combination therapies that offer both short-acting and long-acting bronchodilators in a single inhaler. This trend is driven by the need for better disease management and improved patient compliance. The market is also witnessing an increase in the use of biologic drugs for the treatment of severe asthma.
Local special circumstances: Kuwait has a high prevalence of respiratory diseases, which is attributed to various factors such as air pollution, smoking, and genetic predisposition. The country also has a high incidence of allergies, which can trigger respiratory symptoms. These local special circumstances have contributed to the growth of the bronchodilator drugs market in Kuwait.
Underlying macroeconomic factors: The healthcare sector in Kuwait is well-developed and is supported by the government. The country has a high per capita income, which allows patients to afford expensive bronchodilator drugs. The government also provides subsidies for essential medicines, including bronchodilator drugs, which makes them more affordable for patients. The aging population in Kuwait is also driving the growth of the bronchodilator drugs market as respiratory diseases are more common in older adults.In conclusion, the bronchodilator drugs market in Kuwait is growing steadily due to factors such as customer preferences, local special circumstances, and underlying macroeconomic factors. The shift towards combination therapies and the use of biologic drugs are some of the trends that are shaping the market in Kuwait. The government support and the high per capita income of the country are also contributing to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
